An explanation of the design, efficacy, and adverse events of L-MIND, a trial investigating a combination treatment for R/R DLBCL.
Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL
December 10th 2023In the final analysis of the phase 2 ELM-2 trial, odronextamab monotherapy showed encouraging efficacy, with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Khan Discusses Third-Line Novel Treatment Approaches for R/R DLBCL
December 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Cyrus M. Khan, MD, and participants discussed the case of a patient with diffuse large B-cell lymphoma who progressed after complete remission on standard-of-care frontline therapy, then had stable disease after receiving polatuzumab vedotin, bendamustine, and rituximab.
Read More
Discussing Subgroup Responses to Immunotherapy and R-CHOP in DLBCL
December 6th 2023In the second article of a 2-part series, Herbert A. Eradat, MD, discusses further considerations with adding polatuzumab vedotin in combination chemotherapy in certain subgroups of patients with diffuse large B-cell lymphoma.
Read More
Timing of DLBCL Relapse Linked With Evolutionary Patterns
December 1st 2023A report suggests the cause behind different outcomes among patients with diffuse large B-cell lymphoma who relapse, highlighting that patients whose cancer relapses shortly after treatment tend to have worse responses to additional chemotherapy-based treatment.
Read More